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Unstructured Abstract:  
Studies from Scotland and Canada confirm large increases in the incidence of pregnancies 
complicated by pre-gestational type 1 diabetes (T1D). With this increased antenatal workload 
comes more specialization and staff expertise, which may be important as diabetes 
technology use increases. While euglycemia remains elusive, and obstetrical intervention 
(earlier delivery, increased operative deliveries) is increasing, there have been some notable 
successes in the past 5-10 years. These include a decline in the rates of congenital anomaly 
(Canada), in stillbirths (UK) and substantial reductions in maternal hypoglycemia (both 
moderate and severe) across many countries. However, pregnant women with T1D still spend 
approximately 30-45% of the time (8-11 hours/day) hyperglycemic during the second and 
third trimesters. The duration of maternal hyperglycemia appears unchanged, in routine 
clinical care, over the past decade. This ongoing fetal exposure to maternal hyperglycemia 
explains the persistently rates of large for gestational age (LGA), neonatal hypoglycemia and 
neonatal intensive care unit (NICU) admissions in T1D offspring. The CONCEPTT trial 
found that pregnant women using real-time Continuous Glucose Monitoring (CGM) spent 
5% less time (1.2 hours/day) hyperglycemic during the third trimester, with clinically 
relevant reductions in LGA, neonatal hypoglycemia and NICU admissions. This perspective 
will review the progress in our understanding of the intensive glycemic treatment of T1D 
pregnancy, focusing in particular on the recent technological advances in CGM and 
automated insulin delivery. It suggests that, even with advanced diabetes technology, optimal 
maternal dietary intake is needed to minimise the neonatal complications attributed to 







Prospective nationwide studies confirm that despite widespread suboptimal glycemic control, 
the majority of women with pre-gestational type 1 diabetes deliver live born babies (1, 2). 
Whilst complications attributed to maternal hyperglycemia throughout pregnancy; namely 
rates of large for gestational age (LGA), preterm delivery and neonatal intensive care unit 
(NICU) admissions remain high, almost 95% of women with T1D leave hospital with a 
liveborn infant. A large population-based study from the United Kingdom reported a 
consistent reduction in stillbirths, from 25.8 to 10.7 per thousand births, in women with pre-
gestational diabetes over the past decade (3). The absolute risk of stillbirth in T1D is now 
between 10–13 per thousand births, which although higher than the background maternity 
population risk of <5 per thousand, is an important success. A Canadian study reported a 23% 
decline in the rates of congenital anomaly, but without improvement in perinatal mortality 
(4). In contrast, a contemporary study from Scotland found no improvements in stillbirth or 
perinatal mortality for women with diabetes (5). Both the Canadian and Scottish studies 
describe significant increases in the incidence of pregnancies complicated by pre-gestational 
diabetes over the past 15 years (a doubling in Canada and a 44% increase in T1D and 90% 
T2D in Scotland) (4, 5).  
The reasons for reductions in stillbirths are most likely multifactorial including for example; 
improvements in the provision and uptake of prepregnancy care, tighter glycemic targets 
(HbA1c <6.5% (48 mmol/mol) and increased specialization of antenatal diabetes care. Since 
2002-03, the number of UK diabetes maternity clinics has reduced (from 231 to 155), while 
the incidence of pregnancies complicated by pre-gestational diabetes has increased. This 
means that there are now twice as many women with pre-gestational diabetes per clinic. 
Balanced with the increased antenatal clinic workload is a more focused concentration of 
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staff expertise, which may be important as diabetes technology becomes more complex. It 
also means a need for more efficient antenatal diabetes care provision.  
Current antenatal diabetes care pathways involve frequent clinic visits with an (obstetrician, 
endocrinologist, diabetes educator, diabetes specialist midwife, diabetes dietitian) typically 
every 2 weeks from 8-36 weeks gestation and weekly until delivery (6). This means 15 
scheduled face-to-face visits, requiring women to take a morning, afternoon or full day off 
work and/or arrange childcare provision. In addition, there are frequent between visit contacts 
(face-to-face, telephone and email) with the diabetes educator for glycemic management. The 
increased use of technology has the potential to deliver antenatal diabetes care more 
efficiently to a larger number of women and more effectively in terms of optimising day-to-
day glucose control. In a background of increasing demands on limited health care resources 
cost-effective technologies, which enable women to effectively self-manage before, during 
and between their pregnancies, are urgently needed. This perspective will review the progress 
in our understanding of the intensive glycemic treatment of T1D pregnancy, focusing in 
particular on the recent technological advances in CGM and automated insulin delivery.  
Prepregnancy care 
While hyperglycemia at any stage of pregnancy is associated with increased risk of neonatal 
complications, early pregnancy (the first six to seven weeks), when organogenesis of major 
cardiac and neural tube structures occur is particularly crucial (7). Hyperglycemia, lack of 
folic acid supplementation and taking potentially harmful medications (ACE inhibitors, 
statins), all contribute to increased rates of cardiac and neural tube anomalies. Tennant et al 
demonstrated that, even in normally formed offspring without congenital anomaly, the 
increased risk of fetal and infant death is still largely moderated by maternal glycemic control 
(8).  Periconception HbA1c levels above 6.3% (43mmol/mol) are associated with increased 
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odds of congenital anomaly and levels above 6.6% (49mmol/mol) with fetal and infant death 
(8). Therefore, prepregnancy care (PPC) is universally recommended, to optimise maternal 
glycemia and reduce the most serious adverse pregnancy outcomes.  
For women with T1D, the key components of PPC include preconception folic acid 
supplementation, the lowest HbA1c level that is safely achievable and stopping potentially 
harmful medications (6). Our own work has shown that even with intensive antenatal support, 
women who do not attend PPC clinics do not achieve the same glycemic control as those who 
began before pregnancy (9). A concern is that PPC clinics benefit educated, advantaged 
women and fail to engage disadvantaged who should be prioritised to ensure fairness. This is 
supported by the UK National Pregnancy In Diabetes (NPID) audit data which shows that 
among women living in the most advantaged areas, 75% take 5mg preconception folic acid 
and 25% achieve the NICE recommended HbA1c target of <6.5% (48mmol/mol)(3). Fewer 
than 10% of women from disadvantaged areas achieve the same HbA1c target. More 
innovative approaches such as Mobile health (mHealth) technology to raise womens 
awareness of and engagement with PPC should be targeted at disadvantaged groups.  
Evaluation of a Danish app designed for women attending a diabetes pregnancy clinic, 
reported that 75% of women had downloaded it, with almost half having engaging with it, 
prior to pregnancy (10).  
Assessing glucose control in pregnancy – what’s the best test? 
It is widely accepted that HbA1c levels can be misleading when evaluating individual rather 
than population level glucose control as individuals with the same mean glucose can have 
different HbA1c values (11). Furthermore, HbA1c does not reﬂect intra- and interday 
glycemic excursions or quantify the postprandial hyperglycemia that contributes to fetal and 
neonatal complications. In women without diabetes, HbA1c is lower during pregnancy, due 
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to lower mean glucose, increased erythropoiesis and shortened red cell life span (12). Extant 
literature suggests an artefactual lowering of HbA1c (approximately 0.5%) in pregnancy that 
is unrelated to maternal glycemia (13, 14). However, despite its well-recognized gestational 
limitations (13, 14), HbA1c is routinely used to assess maternal glycemia, potentially 
providing false reassurance to women and clinicians.  
Data from our own clinic population of 102 T1D pregnant women found that the relationship 
between mean self-monitored blood glucose (SMBG) and HbA1c changed in early 
pregnancy. We found an even larger fall in HbA1c, of approximately 1% (11mol/mol), 
between 12 and 20 weeks gestation that was also unrelated maternal glucose control (Table 
1). This means that a mean SMBG of 144mg/dl (8.0 mmol/L) was associated with an HbA1c 
of 6.8% (51mmol/mol) at 12 weeks and with an HbA1c level of 5.9% (41mmol/mol) at 24 
weeks gestation, supporting the view that maternal HbA1c does not adequately reflect 
antenatal glycemic control (15).  
HbA1c can be now calculated according to estimated average glucose (eAG) from CGM 
measures rather than measured by laboratory assay. Law et al found that during pregnancy, a 
1% (11mmolmol) difference in maternal HbA1c is equivalent to 12mg/dl (0.66 mmol/L) in 
average glucose levels (16). Thus, HbA1c is also associated with lower eAG in pregnancy, 
leading to a recommendation that pregnancy specific calculations be used and reported. This 
difference between the pregnancy-specific and non-pregnancy eAG increase with increasing 
HbA1c values, which means that HbA1c values can be particularly misleading and falsely 
reassuring in those with suboptimal glycemic control. These authors suggest that patients and 
clinicians should aim for eAG of 6.4-6.7mmol/L to minimise risk of LGA (16). This practical 
solution is applicable to SMBG users (with memory glucometers to calculate a mean glucose 
over 7-14 days) as well as insulin pump and CGM users. 
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Novel markers of glycemic control 
1,5-anhydroglucitiol (1,5-AG) has been approved by the Food and Drug Administration 
(FDA) for intermediate assessment of glycaemic control and may have a role during 
pregnancy, reflecting post-prandial glycemic excursions (17). More recently, the complement 
inhibitor, glycated CD59 has been suggested as a novel marker of glycemic control (18). It 
may be useful for identifying pregnancies complicated by hyperglycemia and for identifying 
mothers at increased risk of delivering LGA newborns. Approximately 75% of LGA infants 
were born to mothers with a 7-fold increase in median CD59 levels but apparently “normal” 
results during an oral glucose tolerance test (18). Whether or not these will prove useful in 
clinical practice is unclear, especially as direct CGM measures become increasingly 
available.  
CGM metrics 
The vast array of direct CGM metrics facilitates more detailed objective measurement of day-
to-day glucose control but complicates our definition of “good” glycemic control. HbA1c 
lends itself to clear thresholds with almost all professional organizations suggesting targets of 
<6.5% (48mmol/mol) during pregnancy. Similar targets for CGM measures have not yet been 
established. Outside of pregnancy there is a move towards standardization of definitions for 
time-in-range (TiR), and both hypo and hyperglycemic excursions (19). This allows for 
between study comparisons and is particularly relevant for T1D pregnancy where CGM data 
are limited. Suggested CGM metrics for pregnancy in relation to the recent international 
consensus statement are proposed in Table 2.  
CGM accuracy is most commonly assessed using the mean absolute relative difference 
(MARD) between CGM and SMBG values. A MARD ≤10% is optimal for research and for 
clinical decision making and is applicable regardless of pregnancy status. The percentage TiR 
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is usually 70-140mg/dl or 63-140mg/dl during T1D pregnancy, lower than the 70-180mg/dl 
(3.9-10.0mol/L) range outside pregnancy. The consensus statement suggests categorizing the 
level of hypoglycemia into levels of increasing severity from Level 1 to Level 3. Level 1 is an 
alert of potential impending hypoglycemia. Level 2 is a glucose level <54mg/dl (3.0mmol/L) 
with or without symptoms. Level 3 is a severe hypoglycemia episode requiring assistance. As 
fasting glucose is lower during pregnancy, and sensor accuracy is lower in the hypoglycemic 
range, paying attention to the lower threshold is important when quantifying hypoglycemia in 
pregnancy. Diabetes pregnancy clinicans need to consider whether to adapt the standardized 
threholds or to establish pregnancy specific ones using the more stringent T1D pregnancy 
thresholds of 63mg/dl (3.5mmol/L) and 50mg/dl (2.8mmol/L).  
Glycemic control in pregnant women 
It is a decade since we first described the longitudinal CGM measures during T1D pregnancy. 
These data provided some of the first insights into direct fetal exposure to maternal 
hyperglycemia (20). Our original CGM data indicated that T1D women spent only 43% TiR 
of 70-140mg/dl (10.4 hours/day) in early pregnancy rising to 56% (13.5 hours/day) in late 
pregnancy (20). Despite enormous efforts, they still spent 33% of the time (8 hours/day) 
hyperglycaemic >140mg/dl during the third trimester. Maternal hypoglycemia (<70mg/dl) 
was widespread, approximately 13% (3 hours/day). Very comparable findings were reported 
in women with T1D from a Danish CGM trial using SMBG measures; 58% in target (70-
144mg/dl), 14% below 70mg/dl, and 28% above the slightly higher 144mg/dl hyperglycemic 
threshold (21) .  
Comparing these with the recent CONCEPTT data, the third trimester TiR (63-140mg/dl) is 
largely unchanged; 61% in the SMBG group (22) (Figure 1a). The most striking difference is 
the substantial reduction in maternal hypoglycemia (Figure 1b). The CONCEPTT CGM 
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group spent only 3% time below 63mg/dl compared to 13%-14% time below 70mg/dl in the 
earlier CGM studies. This is not just due to differences in sensor accuracy or hypoglycemia 
thresholds as clinical hypoglycaemia events and severe hypoglycaemia episodes were also 
reduced, most likely due to increasing use of insulin analogues (23, 24).  
However, the fetal exposure to maternal hyperglycemia is essentially unchanged in routine 
care. Women using CGM spent 5% (1.2 hours/day) less time hyperglycemic (27 vs 32%) at 
34 weeks gestation (Figure 1c) (22). However, pregnant women using only SMBG still spent 
45% time (11.5hours/day) hyperglycemic at 24 weeks gestation, which explains why LGA 
rates remain high (25).  
CGM allows for unprecedented characterisation of the day-to-day, within-day and between-
day glycemic variability, with a vast array of potential metrics assessing the amplitude, 
frequency and duration of deviations above and below target range. Most of these measures 
are highly correlated and dependent on mean glucose, making it difficult to accurately assess 
the independent contribution of glycemic variability beyond overall glucose control. 
Importantly, the risk of maternal and/or fetal complications increase both with amplitude and 
with duration of the glycemic excursion yet most of the traditional glycemic variability 
metrics ignore the time axis of CGM data. More sophisticated statistical methods (time series, 
functional data analysis) may provide new insights into which time periods (day vs night) to 
target glycemic interventions (26). 
Glycemic control in women planning pregnancy 
However, even with specialist PPC clinics and motivated advantaged attendees, only a third 
to a half of attendees achieve target HbA1c levels before conception (9, 27). The recent 
CONCEPTT trial specifically evaluated the effectiveness of CGM for improving glucose 
control in women planning pregnancy. Previous studies had evaluated the role of 
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retrospective and/of intermittent real-time CGM during pregnancy (21, 28), but did not 
include women planning pregnancy. Full details of the study protocol and results are 
published elsewhere (22, 29). In brief, there were 53 women assigned to CGM and 57 to 
SMBG (control). They had long duration of diabetes (18 and 19 years respectively), with 
most (approximately 75%) using insulin pump therapy. Their rates of microvascular 
complications were high (37%). Importantly, most women were already overweight or obese, 
with only 40% having a preconception body mass index (BMI) of ≤25 kg/m2.  
The frequency of CGM use (Guardian or MiniMed Minilink system) was reasonably high 
over the first three months (median 6.7 days) with some attenuation over six months (median 
6.2 days). HbA1c fell in both groups (7.6% (59mmol/mol) to 7.1% (54mmol/mol) and 7.3% 
(56mmol/mol) in the CGM and SMBG groups respectively) with 50% of CGM and 40% of 
SMBG women reaching target HbA1c levels. However, as both groups improved, the 
between group differences were small and not statistically significant. Likewise, although the 
direct CGM measures favored CGM, with greater reductions in mean glucose (from 158 to 
144mg/dl or 8.8 to 8.0mmol/L) and more of an increased TiR of 63-140mg/dl (from 42 to 
48%), these were not statistically significant. Thirty four women conceived (17  CGM, 17 
control) and their glucose control (mean HbA1c at confirmed pregnancy 6.9% vs 7.0%, 52 vs 
53mmol/mol) and pregnancy outcomes did not differ. Although the numbers of women who 
conceived are very small, there was a surprising 3kg less gestational weight gain in the CGM 
group (10.4 vs 13.4kg from confirmed pregnancy to 34 weeks gestation), suggesting that 
CGM users may have been making substantial dietary adjustments.  
Despite all these adjustments to diet and glycemia, 75% of these babies had a composite poor 
outcome, which included miscarriage, LGA, neonatal hypoglycemia, hyperbilirubinemia, 
respiratory distress and NICU admission. These data do not mean that CGM and/or sensor-
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augmented pump therapy are ineffective and but they highlight that despite increased diabetes 
technology, euglycemia in T1D pregnancy remains elusive before and during pregnancy.  
Insulin delivery; pens vs pumps 
An unexpected finding from CONCEPTT was that the treatment effect of CGM was 
comparable in women using insulin pumps and multiple daily injections (MDI). This 
supports recent data advocating increased CGM use in MDI users outside of pregnancy (30). 
Indeed, in CONCEPTT, the CGM MDI users had the best overall glucose control, with 
almost 70% TiR (63-140mg/dl), 26% time > 140mg/dl and 3% time < 63mg/dl (Table 3). 
Furthermore, their glycemic variability was comparable to that of insulin pump users. Some 
authors have suggested that insulin pump therapy has not yet lived up to the expectations of 
health care professionals (31). The randomized studies in pregnancy are outdated, with older 
pumps and MDI regimes, small sample sizes and not applicable to current clinical practice 
(32). More recent descriptions are observational and subject to bias and confounding factors 
(31, 33). Pumps are now in such widespread clinical use among women of reproductive 
years, that an adequately powered, randomized trial would not be feasible in most antenatal 
diabetes clinics, with appropriate diabetes technology infrastructure and educator expertise.  
A pragmatic randomized controlled trial evaluating the relative effectiveness of pumps over 
MDI in non-pregnant UK participants found a mean change in HbA1c at 24 months of −0.8% 
and −0.4% (-9 and 0.45 mmol/mol) for pump and MDI users respectively (34). After 
adjustment for confounders, the difference in favor of pump users was smaller −0.24% (−2.7 
mmol/mol) and not statistically significant. The accompanying psychosocial evaluation found 
that pump users showed greater improvement in diabetes treatment satisfaction, more dietary 
freedom and fewer diabetes hassles (35). This supports an emerging point of view that pump 
therapy is more beneficial for psychosocial outcomes than for glycemic outcomes. CGM, 
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with all its alarms and annoyances may be more effective for focusing the mind on 
minimising glycemic excursions.  
Recent developments in CGM accessibility 
Whilst there have been incremental improvements in sensor accuracy and usability over the 
past decade, there have been three key developments in terms of CGM accessibility. These 
include a growing evidence base regarding the clinical effectiveness in MDI users (30), the 
FDA approval of CGM measures for insulin dosing and the introduction of the Freestyle 
Libre, the first factory calibrated, intermittent glucose monitoring system (30, 36). Data from 
the T1D Exchange registry showed very little CGM use (<10%) compared to widespread 
(60%) insulin pump use during 2013-14 (37). However, the increasing recognition that CGM 
benefits both pump and MDI users means that CGM is becoming more applicable for day-to-
day glycemic management for a wider patient population (22, 30).  
The FDA endorsement of real-time CGM (specifically the Dexcom G5) for replacing SMBG 
is also an important step forwards. Whilst calibration and some checking of SMBG is still 
recommended, particularly during hypoglycemia, exercise and driving, both the clinical and 
the cost-effectiveness of CGM will be greatly enhanced with sensors accurate enough for pre-
meal insulin dosing. The longer duration of newer generation sensors, lasting for up to ten 
days, will benefit users and payers and further improve CGM accessibility.  
However, the real game-changer is the introduction of the Freestyle Libre (Abbott Diabetes 
Care) intermittent glucose monitoring system (36). The sensors last 14 days without the need 
for additional SMBG calibration tests. It is so easy and intuitive that it is marketed direct to 
consumers (without the need for physician recommendation) and neither patient nor staff 
training is required. When it was first introduced in the UK, there was such overwhelming 
demand that the early supply was inadequate requiring new manufacturing premises to be 
13 
 
built. It is also the first CGM to obtain a specific label for use during pregnancy. A study 
among 74 pregnant women (39 GDM, 24 type 1 and 11 type 2 diabetes) across 13 sites (9 
UK and 4 Austrian) demonstrated that, as expected, sensor accuracy, assessed over 14 days at 
various gestational ages is comparable (MARD of approximately 12%) in pregnant and non-
pregnant users (38). We found that similar agreement between CGM sensor accuracy for 
pregnant and non-pregnant users of the Navigator sensor when compared to plasma glucose 
(39). Whilst other sensors may not have specific licenses for use in pregnancy, it seems that 
accuracy issues are sensor specific and applicable to pregnant and non-pregnant users. The 
professional version of the Freestyle Libre (available in the USA) will improve the 
documentation of glycemic profiles in pregnancy. It provides 14-day masked glucose profiles 
without requiring SMBG, making it an affordable research tool. 
The obvious appeal of the Freestyle Libre in clinical practice is the lack of alarms and 
burdens that are associated with real-time CGM. Data from the T1D exchange indicate that 
use of real-time CGM wanes over time and that optimal use as seen in the setting of RCTs is 
not widespread (37). If real-time CGM is a high cost, high maintenance diabetes companion, 
the Freestyle Libre is its low cost, low maintenance alternative.  Although it still provides 
real-time continuous glucose data on-demand (by scanning the reader), it does not alarm to 
alert users of out of range or rapidy changing glucose levels.  
Real-world data provided by the device manufacturers suggest that the benefits on glucose 
control increase with more frequent glucose checking (36). The estimated HbA1c reductions 
were most marked (from 8% to 6.7% or 64 to 50 mmol/mol) in users with the most frequent 
glucose checks (increasing from 4 to 48 checks per day!). The average user performed 16.3 
checks daily, which is clearly higher than an average SMBG user. The role of Freestyle Libre 
in T1D pregnancy is yet to be determined and in particular whether it is as effective as real-
time CGM for improving neonatal outcomes (22). The Freestyle Libre may be an excellent 
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“entry level” technology for patients not wanting the demands of real-time CGM. It may also 
help clinicans to determine which patients are candidiates for more advanced CGM, sensor 
augmented/threshold suspend pump and automated insulin delivery systems. 
Automated insulin delivery  
Technological advances in CGM have made the promise of automated insulin delivery, also 
known as artificial pancreas or closed-loop, a potential clinical therapeutic reality. A recent 
systematic review and meta-analyses of 585 participants from 27 outpatient studies found 
consistent glycemic improvements with 12.6% increased TiR (3 hours/day) across a variety 
of closed-loop systems (40). However, thus far, most of the improvement is in overnight 
glycemia and the between-group differences are very dependent on the level of glucose 
control in the comparator arm. We also found that overnight closed-loop was associated with 
a 15% higher overnight time-in-target (75 vs 60%) during T1D pregnancy (41). Preliminary 
data from this first home closed-loop study, suggest feasibility of day-and-night closed-loop 
throughout pregnancy, including in hospital during labour and delivery. Most women chose 
to continue closed-loop after the randomized trial, with generally high levels of satisfaction 
despite frequent alarms and technical glitches (42).  
A subsequent randomized evaluation of day-and-night closed-loop in T1D pregnancy, found 
that closed-loop was as effective, but not superior to sensor-augmented pump therapy. 
Women spent 60% TiR during both interventions in the second trimester, but closed-loop 
reduced the extent and duration of hypoglycemia, suggesting that it is potentially safer. We 
also found that women who entered pregnancy with better glucose control achieved a fairly 
constant 70-75% time-in-range (63-140mg/dl) across pregnancy. Women with suboptimal 
glucose control (HbA1c >7.5% or 53mmol/mol) never caught up and only achieved 65-70% 
time-in-range after 28 weeks gestation. They took longer to become confident using the study 
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devices and never quite reached the same glycemic control suggesting that diabetes self-
management education is still required for optimal use of hybrid closed-loop systems (11). 
Other investigators have also warned that automated insulin delivery should not be 
considered a hands-off option, and should be accompanied by appropriate high quality 
dietary and diabetes education (11). This is particularly important during pregnancy when the 
tight post-prandial glucose targets require meticulous attention to carbohydrate estimation 
and bolusing at least 15-30 minutes before eating (43). 
As one in two women with T1D are now entering pregnancy overweight or obese, the 
importance of optimal dietary intake cannot be overstated (3, 22). Higher pre-pregnancy BMI 
and higher gestational weight gain, independent of BMI and glycemic control, is associated 
with increasing neonatal birth weight (44). We found that almost half of the total daily 
carbohydrate intake of UK participants in the CONCEPTT trial was from “non-
recommended” high sugar (biscuits, chocolate, and confectionary) sources. This means that 
these women, half of whom were overweight or obese before pregnancy, ate approximately 
90g per day of “sweet treats”. Even the most aggressive closed-loop algorithms and fast-
acting insulin analogues cannot safely match these dietary intakes (45). A high-quality 
dietary intervention trial (of Mediterranean diet or low glycemic index carbohydrates) is as 
important to guide clinical practice in T1D as in GDM pregnancy. A recent systematic review 
and metaanalyses found 19 randomised controlled trials of dietary interventions in GDM 
pregnancy (46). While dietary advice is an essential component of clinical management in 
T1D pregnancy, there are no high quality dietary interventions and none to guide optimal use 
of CGM, pumps and closed-loop. Whilst diabetes technology, may add an additional 5-10% 
time in target range (and possibly more for those with suboptimal glucose control) in T1D 
pregnancy, addressing maternal dietary intake is imperative to minimise the immediate and 
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Table 1: Changes in mean glucose, HbA1c and percentage of capillary glucose levels 




















12 weeks  7.8 (1.5) 6.8 (1.0) 51 (11) 39.9 (15.7) 
16 weeks  7.4 (1.2) 6.3 (0.9) 45 (10) 35.2 (13.0) 
20 weeks 7.3 (1.1) 5.9 (0.8) 41   (9) 35.1 (13.0) 
24 weeks 7.4 (1.0) 5.8 (0.8) 40   (9) 35.2 (13.8) 
28 weeks  7.3 (1.1) 5.9 (0.8) 41   (9) 35.4 (13.3) 
32 weeks 7.1 (1.0) 5.9 (0.7) 41   (8) 33.8 (12.3) 
‡ The mean gestational age at booking was 7.2 ±2.2 weeks with 80 (78%) women seen at 8 

























Table 2: Consensus statement recommendations with suggestions for T1D pregnancy 
 Non-pregnant Pregnant 
Data sufficiency  70-80% of possible CGM data 70-80% of possible CGM data 
Data duration Miniumum of 2-weeks  Not determined 
Time blocks 24hr (midnight to midnight) 24hr (midnight to midnight) 
Nighttime  24.00-06.00am 24.00-06.00am or 23.00-07.00hr 
Daytime 06.00-24.00 06.00-24.00 or 07.00-23.00hr 
Overall control Mean glucose Mean glucose 
% Time in range (TIR) 70-180mg/dl (3.9-10.0mmol/L) 70-140mg/dl (3.9-7.8mmol/L) 
 70-140mg/dl (3.9-7.8mmol/L) 63-140mg/dl (3.5-7.8mmol/L) 
Hyperglycaemia – level 1 >180mg/dl (10.0mmol/L) >140mg/dl (7.8mmol/L) 
Hyperglycaemia – level 2 >250mg/dl (13.9mmol/L) >180mg/dl (10.0mmol/L) 
High glucose exposure High Blood Glucose Index  High Blood Glucose Index  
Hypoglycemia – level 1 <70-54mg/dl (3.9-3.0mmol/L) <70-54mg/dl (3.9-3.0mmol/L) or 
63-50mg/dl (3.5-2.8mmol/L) 
Hypoglycemia – level 2 <54mg/dl (3.0mmol/L) <54mg/dl (3.0mmol/L) or 
<50mg/dl (2.8mmol/L) 
Hypoglycemia – level 3 Severe Hypoglycemia Severe Hypoglycemia 
Low glucose exposure Low Blood Glucose Index  Low Blood Glucose Index  
Hypoglycemic event 15 minutes duration 15 minutes duration 
Prolonged hypoglycemia 120 minutes  120 minutes  
   
Glycemic variability    
SD Not reported <25mg/dl suggested 
CV <36% (stable glycemia) <36% (stable glycemia) 
For research purposes   
Area under the curve 
(AUC) 
AUC level 1 and 2 
hyperglycemia 
AUC level 1 and 2 hyperglycemia 
 AUC level 1 and 2 hypoglycemia AUC level 1 and 2 hypoglycemia 
Composite glycemic trial 
outcomes  
HbA1c or TIR and level 2 
hypoglycemia 
TIR and level 2 hypoglycemia 
Broader composite 
outcomes 
HbA1c or TIR + hypoglycemia + 
lipids+BP+weight gain 
TIR + hypoglycemia + gestational 
weight gain+obstetric/neonatal 
outcomes 






Table 3: Continuous glucose monitoring (CGM) measures among women in  
CONCEPTT using insulin pump and multiple daily injections (MDI) during pregnancy  
Pump users (N=98) 
 10-11 weeks gestation 34-35 weeks gestation 
 CGM Control CGM Control 
 N=50 N=48 N=35 N=37 
Mean glucose mg/dl 131±22 133±22 121±18 126±16 
% Time in target range* 53±12 54±14 66±13 62±14 
% Time >140mg/dl 39 (26-47) 39 (29-49) 27 (20-37) 32 (27-41) 
% Time < 63mg/dl 8 (3-13) 6 (3-10) 3 (1-7) 4 (2-7) 
Hypoglycemia episodes¥ 0.8 (0.6-1.0) 0.7 (0.5-0.9) 0.5 (0.3-0.8) 0.5 (0.4-0.7) 
CV % 42 (37-47) 40 (36-46) 31 (28-37) 35 (29-40) 
SD mmol/L 3.0 (2.5-3.4) 3.1 (2.5-3.6) 2.2 (1.8-2.5) 2.4 (2.0-3.0) 
MDI users (N=116) 
 10-11 weeks gestation  34-35 weeks gestation  
 CGM Control CGM Control 
 N=57 N=59 N=42 N=40 
Mean glucose mg/dl 131±22 139±18 121±14 126±7.0 
% Time in target*  50±13 50±13 69±13 61±17 
% Time >140mg/dl 39 (30-49) 41 (34-51) 26 (17-36) 31 (24-39) 
% Time < 63mg/dl 8 (5-17) 6 (2-12) 3 (1-6) 5 (2-9) 
Hypoglyaemia episodes¥ 0.8 (0.6-1.0) 0.7 (0.3-0.9) 0.5 (0.3-0.8) 0.5 (0.3-0.8) 
CV % 43 (39-48) 43 (36-49) 33 (28-37) 34 (29-38) 
SD mmol/L 3.2 (2.7-3.6) 3.2 (2.7-3.9) 2.2 (1.8-2.5) 2.3 (2.0-2.8) 
Data are mmean ±SD and median (interquartile range) as appropriate. 
*Time in target range for T1D pregnancy was defined as 63-140mg/dl (3.5-7.8mmol/L). 
¥Hypoglycemia episodes were defined as CGM levels <63mg/dl for at least 20 minutes. Distinct 





Figure 1: Continuous Glucose Monitoring (CGM) measures of women with T1D during 
pregnancy in CONCEPTT 
1A: Time in T1D pregnancy target range 63-140mg/dl (3.5-7.8mmol/L) 
The Home Glucose Monitoring (HGM) control group spent 52% time in target at baseline 
(12.5 hours/day) rising to 61% (14.6 hours/day) at 34 weeks. The CGM group spent 52% 
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Figure 1b: Time spent hyperglycaemic > 140mg/dl (7.8mmol/L).  
The Home Glucose Monitoring (HGM) control group spent 40% time hyperglycaemic at baseline (9.6 
hours/day) reducing to 32% (7.7 hours/day) at 34 weeks. The CGM group spent 39% time in target at 






Figure 3: Time spent hypoglycemic < 63mg/dl (3.5mmol/L).  
The Home Glucose Monitoring (HGM) control group spent 8% time hyperglycaemic at 
baseline (1.9 hours/day) reducing to 4% (1.0 hours/day) at 34 weeks. The CGM group spent 
6% time in target at baseline (1.4 hours/day) reducing to 3% (0.7 hours/day) at 34 weeks 
gestation; p=0.10.  
 
 
 
 
 
 
